Table 7. Characteristics of clinical trials studying tocilizumab in patients with COVID-19.
| Clinical trial ID | Status | Study results | Conditions | Interventions | Locations |
| NCT04335071 | Recruiting | No results available | COVID-19 | Drug: Tocilizumab drug: Placebo | Switzerland |
| NCT04310228 | Recruiting | No results available | COVID-19 | Drug: Favipiravir combined with tocilizumab | China |
| NCT04359667 | Recruiting | No results available | COVID-19 | Drug: Tocilizumab 20 milligrams/milliliters intravenous solution [ACTEMRA] | Croatia |
| NCT04339712 | Recruiting | No results available | COVID-19 | Drug: Anakinra drug: Tocilizumab | Greece |
| NCT04335305 | Recruiting | No results available | COVID-19 | Drug: Tocilizumab biological: Pembrolizumab (MK-3475) | Spain |
| NCT04361552 | Recruiting | No results available | COVID-19 | Other: Best practice biological: Tocilizumab | United States |
| NCT04330638 | Recruiting | No results available | COVID-19 | Drug: Anakinra drug: Siltuximab drug: Tocilizumab | Belgium |